Skip to main content
Coral Laboratories Ltd. logo

Coral Laboratories Ltd. — Investor Relations & Filings

Ticker · 524506 ISIN · INE683E01017 LEI · 33580018OR2STOC8SS52 BSE.NS Manufacturing
Open in API
Filings indexed 3 across all filing types
Latest filing 2026-05-30 Regulatory Filings
Country IN India
Listing BSE.NS 524506

About Coral Laboratories Ltd.

https://corallab.com/

Coral Laboratories Ltd. specializes in the development, manufacture, and marketing of a diverse range of pharmaceutical formulations. The product portfolio encompasses various dosage forms, including tablets, capsules, oral liquids, external preparations such as creams and ointments, and sterile injectables. These offerings address multiple therapeutic areas, including anti-bacterial, analgesic, anti-inflammatory, and gastrointestinal health. The company operates manufacturing facilities that adhere to WHO-GMP standards, ensuring rigorous quality management and compliance with global regulatory requirements. With a focus on providing accessible healthcare solutions, the organization serves a broad client base across domestic and international markets. Research and development efforts are centered on formulation optimization and the expansion of the product pipeline to meet evolving medical needs.

Recent filings

Filing Released Lang Actions
Annua Secretarial Compliance Report for the financial year ended March 31, 2026
Regulatory Filings Classification · 88% confidence The document is an Annual Secretarial Compliance Report prepared under Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, addressed to BSE. It is a compliance certification/attestation by company secretaries rather than the company’s core financial statements or formal annual report. Per the Certification Rule, officer certifications and compliance attestations are classified as Regulatory Filings (RNS).
2026-05-30 English
Board to consider Dividend
Board/Management Information Classification · 90% confidence The document is an intimation to the stock exchange under SEBI (Listing Obligations and Disclosure Requirements) Regulation 29 regarding the scheduling of a Board of Directors meeting, items to be considered (audited results, dividend recommendation, auditor appointments), and trading window closure details. It is an announcement of a board meeting rather than an actual financial report or minutes. This falls squarely under Board/Management Information (MANG).
2026-05-20 English
Coral Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 ....
Regulatory Filings Classification · 85% confidence The document is a statutory intimation under SEBI LODR Regulation 29 notifying BSE of an upcoming Board of Directors meeting. It does not provide results or changes to management (so not a Board/Management change notice under Code MANG) nor does it attach any financial statements itself. It is a regulatory announcement/filing, fitting the fallback category for miscellaneous compliance notices (Regulatory Filings).
2026-05-20 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.